Occurrence of pharmaceutical compounds in urban wastewater: Removal, mass load and environmental risk after a secondary treatment-A review

Science of the Total Environment

Volumn 429, Issue , 2012, Pages 123-155

  Verlicchi, P ^a,b   Al Aukidy, M ^a   Zambello, E ^a,b  

^a UNIVERSITY OF FERRARA   (Italy)

^b Lab Terra and Acqua Tech Water Quality   (Italy)

Author keywords

Activated sludge systems; Environmental risk; Mass load; Pharmaceuticals; Removal efficiency; Urban wastewater

Indexed keywords

ACTIVATED SLUDGE SYSTEMS; ENVIRONMENTAL RISKS; MASS LOAD; REMOVAL EFFICIENCIES; URBAN WASTEWATER;

ACTIVATED SLUDGE PROCESS; ANTIBIOTICS; DRUG PRODUCTS; EFFLUENT TREATMENT; REMOVAL; SURFACE WATERS; WASTEWATER TREATMENT;

EFFLUENTS;

AGENTS AFFECTING LIPID METABOLISM; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIDIABETIC AGENT; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; BARBITURIC ACID DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CONTRAST MEDIUM; CROTAMITON; DIURETIC AGENT; DRUG RESIDUE; HISTAMINE H2 RECEPTOR ANTAGONIST; NEUROLEPTIC AGENT; VALSARTAN;

ACTIVATED SLUDGE; CHEMICAL COMPOUND; DISCHARGE; DRUG; EFFLUENT; ENVIRONMENTAL RISK; POLLUTANT REMOVAL; URBAN AREA; WASTE TREATMENT; WASTEWATER;

ACTIVATED SLUDGE; BIOMASS; CHEMICAL ANALYSIS; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MANAGEMENT; ENVIRONMENTAL MONITORING; ENVIRONMENTAL PROTECTION; HUMAN; NONHUMAN; PH; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TEMPERATURE; URBAN AREA; WASTE COMPONENT REMOVAL; WASTE WATER MANAGEMENT; WATER ANALYSIS;

PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT; SEWAGE; WATER POLLUTANTS, CHEMICAL;

EID: 84862259475     PISSN: 00489697     EISSN: 18791026     Source Type: Journal    
DOI: 10.1016/j.scitotenv.2012.04.028     Document Type: Review

References (160)

1. Alder A.C., Schaffner C., Majewsky M., Klasmeier J., Fenner K. Fate of β-blocker human pharmaceuticals in surface water: comparison of measured and simulated concentrations in the Glatt Valley Watershed, Switzerland. Water Res 2010, 44:936-948.
2. Alexy R., Sommer A., Lange F.T., Kummerer K. Local use of antibiotics and their input and fate in a small sewage treatment plant-significance of balancing and analysis on a local scale vs. nationwide scale. Acta Hydroch Hydrob 2006, 34:587-592.
3. Andersen H., Siegrist H., Sørensen B.H., Ternes T.A. Fate of estrogens in a municipal sewage treatment plant. Environ Sci Technol 2003, 37:4021-4026.
4. Andreozzi R., Marotta R., Paxéus N. Pharmaceuticals in STP effluents and their solar photodegradation in aquatic environment. Chemosphere 2003, 50:1319-1330.
5. Ashton D., Hilton M., Thomas K.V. Investigating the environmental transport of human pharmaceuticals to streams in the United Kingdom. Sci Total Environ 2004, 333:167-184.
6. Batt A.L., Kim S., Aga D.S. Enhanced biodegradation of iopromide and trimethoprim in nitrifying activated sludge. Environ Sci Technol 2006, 40:7367-7373.
7. Baronti C., Curini R., D'Ascenzo G., Di Corcia A., Gentili A., Samperi R. Monitoring natural and synthetic estrogens and activated sludge sewage treatment plants and in a receiving river water. Environ Sci Technol 2000, 34:5059-5066.
8. Baumgarten S., Schroder H.F., Charwath C., Lange M., Beier S., Pinnekamp J. Evaluation of advanced treatment technologies for the elimination of pharmaceutical compounds. Water Sci Technol 2007, 56:1-8.
9. Bendz D., Paxeus N.A., Ginn T.R., Loge F.J. Occurrence and fate of pharmaceutically active compounds in the environment, case study: Hoje River in Sweden. J Hazard Mater 2005, 122:195-204.
10. Bernhard M., Müller J., Knepper T.P. Biodegradation of persistent polar pollutants in wastewater: comparison of an optimized lab-scale membrane bioreactor and activated sludge treatment. Water Res 2006, 40:3419-3428.
11. Boillot C. Évaluation des risques écotoxicologiques liés aux rejets d'effluents hospitaliers dans les milieux aquatiques. Contribution à l'amélioration de la phase "caratérisation des effets". PhD Thesis. Institut National des Sciences Appliquées de Lyon, France, N° d'ordre 2008 ISAL 0021.
12. Bottoni P., Caroli S., Caracciolo A.B. Pharmaceuticals as priority water contaminants. Toxiol Environ Chem 2010, 92:549-565.
13. Brain R., Johnson D., Richards S., Sanderson H., Sibley P., Solomon K. Effects of 25 pharmaceutical compounds to Lemna Gibba using a seven day static-renewal test. Environ Toxicol Chem 2004, 23:371-382.
14. Brown K.D., Kulis J., Thomson B., Chapman T.H., Mawhinney D.B. Occurrence of antibiotics in hospital, residential, and dairy effluent, municipal wastewater, and the Rio Grande in New Mexico. Sci Total Environ 2006, 366:772-783.
15. Carballa M., Omil F., Lema J.M., Liompart M., Garcia-Jares C., Rodriguez I., et al. Behavior of pharmaceuticals, cosmetics and hormones in a sewage treatment plant. Water Res 2004, 38:2918-2926.
16. Carballa M., Omil F., Lema J.M., Llompart M., Garcìa C., Rodriguez I., et al. Behaviour of pharmaceuticals and personal care products in a sewage treatment plant of northwest Spain. Water Sci Technol 2005, 52:29-35.
17. Carucci A., Cappai G., Piredda M. Biodegradability and toxicity of pharmaceuticals in biological wastewater treatment plants. J Environ Sci Heal A 2006, 41:1831-1842.
18. Castiglioni S., Bagnati R., Fanelli R., Pomati F., Calamari D., Zuccato E. Removal of pharmaceuticals in sewage treatment plants in Italy. Environ Sci Technol 2006, 40:357-363.
19. Choi K., Kim Y., Park J., Park C., Kim M., Kim S., et al. Seasonal variation of several pharmaceutical residues in surface water and sewage treatment plants of Han River, Korea. Sci Total Environ 2008, 405:120-128.
20. Cicek N., Franci J.P., Suidan M.T., Vincent U., Manem J. Characterization and comparison of a membrane bioreactor and a conventional activated sludge system in the treatment of wastewater containing high-molecular weight compounds. Water Environ Res 1999, 71:64-70.
21. Cirja M., Ivashechkin P., Schäffer A., Corvini P.F.X. Factors affecting the removal of organic micropollutants from wastewater in conventional treatment plants (CTP) and membrane bioreactors (MBR). Rev Environ Sci Biotechnol 2008, 7:61-78.
22. Clara M., Strenn B., Ausserleiter M., Kreuzinger N. Comparison of the behaviour of selected micropollutants in a membrane bioreactor and a conventional wastewater treatment plant. Water Sci Technol 2004, 50:29-36.
23. Clara M., Kreuzinger N., Strenn B., Gans O., Kroiss H. The solids retention time-a suitable design parameter to evaluate the capacity of wastewater treatment plants to remove micropollutants. Water Res 2005, 39:97-106.
24. Clara M., Strenn B., Gans O., Martinez E., Kreuzinger N., Kroiss H. Removal of selected pharmaceuticals, fragrances and endocrine disrupting compounds in a membrane bioreactor and conventional wastewater treatment plants. Water Res 2005, 39:4797-4807.
25. Cleuvers M. Aquatic ecotoxicity of pharmaceuticals including the assessment of combination effects. Toxicol Lett 2003, 142:185-194.
26. Cleuvers M. Mixture toxicity of the anti-inflammatory drugs diclofenac, ibuprofen, naproxen, and acetylsalicylic acid. Ecotox Environ Safe 2004, 5:309-315.
27. Cleuvers M. Initial risk assessment for three B_blockers found in the aquatic environment. Chemosphere 2005, 59:199-205.
28. Conti F., Cottica D., Negri S., Perissi A., Stella S. Pharmaceuticals removal from urban wastewater by means of biological and physical-chemical treatments in full scale plants. Proc. VI EWRA International Symposium, Water engineering and management in a changing environment Catania, June 29-July 2 2011.
29. Costanzo S.D., Murby J., Bates J. Ecosystem response to antibiotics entering the aquatic environment. Mar Pollut Bull 2005, 51:218-223.
30. Coetsier C.M., Spinelli S., Lin L., Roig B., Touraud E. Discharge of pharmaceutical products (PPs) through a conventional biological sewage treatment plant: MECs vs PECs?. Environ Int 2009, 35:787-792.
31. D'Ascenzo G., Di Corcia A., Gentili A., Mancini R., Mastropasqua R., Nazzari M., et al. Fate of natural estrogen conjugates in municipal sewage transport and treatment facilities. Sci Total Environ 2003, 302:199-209.
32. Deblonde T., Cossu-Leguille C., Hartemann P. Emerging pollutants in wastewater: a review of the literature. Int J hyg Envir Heal 2011, 214:442-448.
33. De Souza S.M.L., De Vasconcelos E.C., Dziedzic M. Environmental risk assessment of antibiotics: an intensive care unit analysis. Chemosphere 2009, 77:962-967.
34. Directive 2000/60/EC of October 23, 2000 of the European Parliament and of the Council establishing a framework for community action in the field of water policy O.J. L 327, December 22, 2000 (FWD).
35. Directice 2006/118/EC of December 12, 2006 of the European Parliament and of the Council on the protection of groundwater against pollution and deterioration.
36. Directive 2008/105/EC (PSD) of December 16, 2008 of the European Parliament and of the Council on environmental quality standards in the field of water policy, amending ad subsequently repealing Council Directives 82/176/EEC, 83/513/EEC, 84/156/EEC, 84/491/EEC, 86/280/EEC and amending Directive 2000/60/EC of European parliament and of the Council.
37. Escher B.I., Baumgartner R., Koller M., Treyer K., Lienert J., McArdell C.S. Environmental toxicology and risk assessment of pharmaceuticals from hospital wastewater. Water Res 2011, 45:75-92.
38. European Community (EC) Technical Guidance Document on Risk Assessment in support of Commission Directive 93/67/EEC on Risk Assessment for new notified substances, Commission Regulation (EC) No 1488/94 on Risk Assessment for Existing Substances and Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market, Parts I, II and IV. European Communities, EUR 20418 EN/1 2003.
39. European Agency for the Evaluation of Medicinal Products (EMEA) Draft Discussion Paper on Environmental Risk Assessment of Non-Genetically Modified Organism (non-GMO) Containing Medicinal Products for Human Use; London 2001.
40. Fatta-Kassinos D., Meric S., Nikolaou A. Pharmaceutical residues in environmental waters and wastewater: current state of knowledge and future research. Anal Bioanal Chem 2011, 399:251-275.
41. Farré M., Ferrer I., Ginebreda A., Figueras M., Olivella L., Tirapu L., et al. Determination of drugs in surface water and wastewater samples by liquid chromatography-mass spectrometry: methods and preliminary results including toxicity studies with Vibro fisheri. J Chromatogr A 2001, 938:187-197.
42. Ferrari B., Paxéus N., Lo Giudice R., Pollio A., Garric J. Ecotoxicological impact of pharmaceuticals found in treated wastewaters: study of carbamazepine, clofibric acid, and diclofenac. Ecotox Environ Safe 2003, 55:359-370.
43. Ferrari B., Mons R., Vollat B., Fraysse B., Paxéus N., Lo Giudice R., et al. Environmental risk assessment of six human pharmaceuticals: are the current environmental risk assessment procedures sufficient for the protection of the aquatic environment?. Environ Toxicol Chem 2004, 23:1344-1354.
44. Foster AL. Occurrence and fate of endocrine disruptors through the San Marco Wastewater treatment plant, Thesis of Master of Science, Texas State University. 2007.
45. Furhacker M. The Water Framework Directive-can we reach the target?. Water Sci Technol 2008, 57:9-17.
46. García-Galán M.J., Díaz-Cruz M.S., Barceló D. Occurrence of sulfonamide residues along the Ebro River basin. Removal in wastewater treatment plants and environmental impact assessment. Environ Int 2011, 37:462-473.
47. Ghosh G.C., Okuda T., Yamashita N., Tanaka H. Occurrence and elimination of antibiotics at four sewage treatment plants in Japan and their effects on bacterial ammonia oxidation. Water Sci Technol 2009, 59:779-786.
48. Ginebreda A., Muñoz I., López de Alda M., Brix R., López-Doval J., Barceló D. Environmental risk assessment of pharmaceuticals in rivers: relationship between hazard indexes and aquatic macroinvertebrate diversity indexes in the Llobregat River (NE Spain). Environ Int 2010, 36:153-162.
49. GWRC Development of an international priority list of pharmaceuticals relevant for the water cycle Available from:, (last access on March 31st 2012). http://edepot.wur.nl/138086.
50. Göbel A., Thomsen A., McArdell C.S., Joss A., Giger W. Occurrence and sorption behavior of sulfonamides, macrolides, and trimethoprim in activated sludge treatment. Environ Sci Technol 2005, 39:3981-3989.
51. Göbel A., Mcardell C.S., Joss A., Siegrist H., Giger W. Fate of sulfonamides, macrolides, and trimethoprim in different wastewater treatment technologies. Sci Total Environ 2007, 372:361-371.
52. Golet E., Xifra I., Siegrist H., Alder A., Giger W. Environmental exposure assessment of fluoroquinolone antibacterial agents from sewage to soil. Environ Sci Technol 2003, 37:3243-3249.
53. Gómez M.J., Martinez Bueno M.J., Lacorte S., Fernandez-Alba A.R., Aguera A. Pilot survey monitoring pharmaceuticals and related compounds in sewage treatment plant located on the Mediterranean cost. Chemosphere 2007, 66:993-1002.
54. Goossens H., Ferech M., Coenen S., Stephens P. Comparison of outpatient systemic antibacterial use in 2004 in the United States and 27 European countries. Clinical Infectious Disease 2007, 44:1091-1095.
55. Gros M., Petrovic M., Ginebreda A., Barceló D. Removal of pharmaceuticals during wastewater treatment and environmental risk assessment using hazard indexes. Environ Int 2010, 36:15-26.
56. Gulkowska A., Leung H.W., So M.K., Taniyasu S., Yamashita N., Yeung L.W.Y., et al. Removal of antibiotics from wastewater by sewage treatment facilities in Hong Kong and Shenzhen, China. Water Res 2008, 42:395-403.
57. Hai F.J., Tessmer K., Nguyen L.N., Kang J., Proce W.E., Nghiem L.D. Removal of micropollutants by membrane bioreactor under temperature variation. J Membrane Sci 2011, 383:144-151.
58. Halling-Sørensen B., Nielsen S.N., Lanzky P.F., Ingerslev F., Holten Lutzhoft H.C., Jorgensen S.E. Occurrence, fate and effects of pharmaceuticals substances in the environment-a review. Chemosphere 1998, 36:357-393.
59. Halling-Sørensen B. Algal toxicity of antibacterial agents used in intensive farming. Chemosphere 2000, 40:731-739.
60. Han G.H., Hur HG, Kim SD Ecotoxicological risk of pharmaceuticals from wastewater treatment plants in Korea: occurrence and toxicity to Daphnia magna. Environ Toxicol Chem 2006, 25:265-271.
61. Henschel K.P., Wenzel A., Diedrich M., Fliedner A. Environmental hazard assessment of pharmaceuticals. Regul Toxicol Pharm 1997, 25:220-225.
62. Hernando M.D., Mezcua M., Fernandez-Alba A.R., Barceló D. Environmental risk assessment of pharmaceutical residues in wastewater effluents, surface waters and sediments. Talanta 2006, 69:334-342.
63. Huggett D.B., Brooks B.W., Peterson B., Foran C.M., Schlenk D. Toxicity of select beta adrenergic receptor-blocking pharmaceuticals (β-blockers) on aquatic organisms. Environ Contam Toxicol 2002, 43:229-235.
64. Jelic A., Gros M., Ginebrenda A., Cespedes-Sánchez R., Ventura F., Petrovic M., et al. Occurrence, partition and removal of pharmaceuticals in sewage water and sludge during wastewater treatment. Water Res 2011, 45:1165-1176.
65. Jia A., Wan Y., Xiao Y., Hu J. Occurrence and fate of quinolone and fluoroquinolone antibiotics in a municipal sewage treatment plant. Water Res 2012, 46:387-394.
66. Jones O.A.H., Voulvoulis N., Lester J.N. Aquatic environmental assessment of the top 25 English prescription pharmaceuticals. Water Res 2002, 36:5013-5022.
67. Jones O.A.H., Voulvoulis N., Lester J.N. Human pharmaceuticals in wastewater treatment processes. Crit Rev Env Sci Tec 2005, 35:401-427.
68. Jones O.A.H., Voulvoulis N., Lester J.N. The occurrence and removal of selected pharmaceutical compounds in a sewage treatment works utilizing activated sludge treatment. Environ Pollut 2007, 145:738-744.
69. Joss A., Andersen H., Ternes T., Richle P.R., Siegrist H. Removal of estrogens in municipal wastewater treatment under aerobic and anaerobic conditions: consequences for plant optimization. Environ Sci Technol 2004, 38:3047-3055.
70. Joss A., Keller E., Alder A., Göbel A., Mcardell C., Ternes T., et al. Removal of pharmaceuticals and fragrances in biological wastewater treatment. Water Res 2005, 39:3139-3152.
71. Karthikeyan K.G., Meyer M.T. Occurrence of antibiotics in wastewater treatment facilities in Wisconsin, USA. Sci Total Environ 2006, 361:196-207.
72. Kasprzyk-Hordern B., Dinsdale R.M., Guwy A.J. The removal of pharmaceuticals, personal care products, endocrine disruptors and illicit drugs during wastewater treatment and its impact on the quality of receiving waters. Water Res 2009, 43:363-380.
73. Khan S.J., Ongerth J.E. Occurrence and removal of pharmaceuticals at an Australian sewage treatment plant. Water 2005, 35-39.
74. Kühn R., Pattard M., Pernak K.D., Winter A. Results of the harmful effects of water of water pollutants to Daphnia magna in the 21 day reproduction test. Water Res 1989, 23:501-510.
75. Kim S., Cho J., Kim I., Vanderford B., Snyder S. Occurrence and removal of pharmaceuticals and endocrine disruptors in South Korean surface, drinking and wastewaters. Water Res 2007, 41:1013-1021.
76. Kimura K., Hara H., Watanabe Y. Removal of pharmaceutical compounds by submerged membrane bioreactors (MBRs). Desalination 2005, 178:135-140.
77. Kimura K., Hara H., Watanabe Y. Elimination of selected acidic pharmaceuticals from municipal wastewater by an activated sludge system and membrane bioreactors. Environ Sci Technol 2007, 41:3708-3714.
78. Kreuzinger N., Clara M., Srenn B., Kroiss H. Relevance of the sludge retention time (SRT) as design criteria for wastewater treatment plants for the removal of endocrine disruptors and pharmaceutical from wastewater. Water Sci Technol 2004, 50:149-156.
79. Kümmerer K., Henninger A. Promoting resistance by the emission of antibiotics from hospitals and households into effluent. Clin Microbiol Infect 2003, 9:1203-1214.
80. Kümmerer K., Steger-Hartmann T., Meyer M. Biodegradability of the anti-tumour agent ifosfamide and its occurrence in hospital effluents and communal sewage. Water Res 1997, 31:2705-2710.
81. Kümmerer K. Antibiotics in the aquatic environment-a review-part I. Chemosphere 2009, 75:417-434.
82. Kümmerer K. The presence of pharmaceuticals in the environment due to human use-present knowledge and future challenges. J Environ Manage 2009, 90:2354-2366.
83. Lee Y.L., Lee S.E., Lee D.S., Kim Y.H. Risk assessment of human antibiotics in Korean aquatic environment. Environ Toxicol Phar 2008, 26:216-221.
84. Lee W., Kang S., Shin H. Sludge characteristics and their contribution to microfiltration in submerged membrane bioreactors. J Memb Sci 2003, 216:217-227.
85. Le Minh N., Khan S.J., Drewes J.E., Stuetz R.M. Fate of antibiotics during municipal water recycling treatment processes. Water Res 2010, 44:4295-4323.
86. Li B., Zhang T. Mass flows and removal of antibiotics in two municipal wastewater treatment plants. Chemosphere 2011, 83:1284-1289.
87. Liebig M., Moltmann J., Knacker T. Evaluation of measured and predicted environmental concentrations of selected human pharmaceuticals and personal care products. Environ Sci Pollut R. 2006, 13:110-119.
88. Lindberg R., Wennberg P., Johansson M., Tysklind M., Andersson B. Screening of human antibiotic substances and determination of weekly mass flows in five sewage treatments plants in Sweden. Environ Sci Technol 2005, 39:3421-3429.
89. Lindberg R.H., Olofsson U., Rendahl P., Johansson M.I., Tysklind M., Andersson B.A.V. Behavior of Fluoroquinolones and Trimethoprime during mechanical, chemical, and active sludge treatment of sewage water and digestion of sludge. Environ Sci Technol 2006, 40:1042-1048.
90. Lindqvist N., Tuhkanen T., Kronberg L. Occurrence of acidic pharmaceuticals in raw and treated sewage and in receiving waters. Water Res 2005, 39:2219-2228.
91. Lishman L., Smyth S.A., Sarafin K., Kleywegt S., Toito J., Peart T., et al. Occurrence and reductions of pharmaceuticals and personal care products and estrogens by municipal wastewater treatment plants in Ontario, Canada. Sci Total Environ 2006, 367:544-558.
92. Marques C.R., Abrantes N., Goncalves F. Life-history traits of standard and autochthonous cladocerans: II. Acute and chronic effects of acetylsalicylic acid metabolites. Environ Toxicol 2004, 19:527-540.
93. Maurer M., Escher B.I., Richle P., Schaffner C., Alder A.C. Elimination of β-blockers in sewage treatment plants. Water Res 2007, 41:1614-1622.
94. McAvoy D.C., Schatowitz B., Jacob M., Hauk A., Eckhoff W.S. Measurement of triclosan in wastewater treatment systems. Environ Toxicol Chem 2002, 21:1323-1329.
95. Metcalfe C.D., Koenig B.G., Bennie D.T., Servos M., Ternes T.A., Hirsch R. Occurrence of neutral and acidic drugs in the effluents of Canadian Sewage treatment plants. Environ Toxicol Chem 2003, 22:2872-2880.
96. Metcalfe C.D., Chu S., Judt C., Li H., Oakes K.D., Servos M.R., et al. Antidepressants and their metabolites in municipal wastewater and downstream exposure in an urban watershed. Environ Technol Chem 2010, 29:79-89.
97. Miège C., Choubert J.M., Ribeiro L., Eusèbe M., Coquery M. Fate of pharmaceuticals and personal care products in wastewater treatment plants-conception of a database and first results. Environ Pollut 2009, 157:1721-1726.
98. Monteiro S.C., Boxall A.B.A. Occurrence and fate of human pharmaceuticals in the environment. Rev Environ Contam T. 2010, 202:53-154.
99. Muñoz I., Gómez-Ramos M.J., Agüera A., García-Reyes J.F., Molina-Díaz A., Fernández-Alba A.R. Chemical evaluation of contaminants in wastewater effluents and the environmental risk of reusing effluents in agriculture. Trends Analyt Chem 2009, 28:676-694.
100. Nakada N., Tanishima T., Shinohara H., Kiri K., Takada H. Pharmaceutical chemicals and endocrine disrupters in municipal wastewater in Tokyo and their removal during activated sludge treatment. Water Res 2006, 40:3297-3303.
101. Onesios K.M., Yu J.T., Bouwer E.J. Biodegradation and removal of pharmaceuticals and personal care products in treatment systems: a review. Biodegradation 2009, 20:441-466.
102. Ort C., Gujer W. Sampling for representative micropollutants loads in sewer systems. Water Sci Technol 2006, 54:169-176.
103. Paxéus N. Removal of selected non-steroidal anti-inflammatory drugs (NSAIDs), gemfibrozil, carbamazepine, β-blockers, trimethoprime and triclosan in conventional wastewater treatment plants in EU countries and their discharge to the aquatic environment. Water Sci Technol 2004, 50:253-260.
104. Peng X., Wang Z., Kuang W., Tan J., Li K. A preliminary study on the occurrence and behavior of sulfonamides, ofloxacin and chloramphenicol antimicrobials in wastewater of two sewage treatment plants in Guangzhou, China. Sci Total Environ 2006, 371:314-322.
105. Perez S., Eichhorn P., Aga D.S. Evaluating the biodegradability of sulphametazine, sulfamethoxazole and trimethoprim at different stages of sewage treatment. Environ Toxicol Chem 2005, 24:1361-1367.
106. Plósz B.G., Leknes H., Thomas K.V. Impacts of competitive inhibition, parent compound formation and partitioning behaviour on antibiotic micro-pollutants removal in activated sludge. Environ Sci Technol 2010, 44:734-742.
107. Quinn B., Gagné F., Blaise C. An investigation into the acute and chronic toxicity of eleven pharmaceuticals (and their solvents) found in wastewater effluent on the cnidarians, Hydra attenuate. Sci Total Environ 2008, 389:306-314.
108. Quintana J.B., Weiss S., Reemtsma T. Pathways and metabolites of microbial degradation of selected acidic pharmaceutical and their occurrence in municipal wastewater treated by a membrane bioreactor. Water Res 2005, 39:2654-2664.
109. Ra J.S., Oh S.Y., Lee B.C., Kim S.D. The effect of suspended particles coated by humic acid on the toxicity of pharmaceuticals, estrogens, and phenolic compounds. Environ Int 2008, 34:184-192.
110. Radjenovic J., Petrovic M., Barceló D. Analysis of pharmaceuticals in wastewater and removal using a membrane bioreactor. Anal Bioanal Chem 2007, 387:1365-1377.
111. Radjenovic J., Petrovic M., Barceló D. Fate and distribution of pharmaceuticals in wastewater and sewage sludge of the conventional activated sludge (CAS) and advanced membrane bioreactor(MBR) treatment. Water Res 2009, 43:831-841.
112. Reif R., Suárez S., Omil F., Lema J.L. Fate of pharmaceuticals and cosmetic ingredients during the operation of a MBR treating sewage. Desalination 2008, 221:511-517.
113. Richardson S.D., Ternes T.A. Water analysis: emerging contaminants and current issues. Anal Chem 2011, 83:4614-4648.
114. Rimkus G.G. Polycyclic musk fragrances in aquatic environment. Toxicol Lett 1999, 111:37-56.
115. Roberts P.H., Thomas K.V. The occurrence of selected pharmaceuticals in wastewater effluent and surface waters of the lower Tyne catchment. Sci Total Environ 2006, 356:143-153.
116. Rodriguez I., Quintana J.B., Carpinterio J., Carro A.M., Lorenzo R.A., Cela R. Determination of acidic drugs in sewage water by gas chromatography-mass spectrometry as tert-butyldimethylsilyl derivatives. J Chromatogr A 2003, 985:265-274.
117. Rosal R., Gonzalo M.S., Boltes K., Letón P., Vaquero J.J., García-Calvo E. Identification of intermediates and assessment of ecotoxicity in the oxidation products generated during the ozonation of clofibric acid. J Hazard Mater 2009, 172:1061-1068.
118. Rosal R., Rodrìguez A., Perdigòn-Melòn J.A., Petre A., Garcìa-Calvo E., Gòmez M.J., et al. Occurrence of emerging pollutants in urban wastewater and their removal through biological treatment followed by ozonation. Water Res 2010, 44:578-588.
119. Ruel S.M., Esperanza M., Choubert J.M., Valor I., Budzinski H., Coquery M. On-site evaluation of the efficiency of conventional and advanced secondary processes for the removal of 60 organic micropollutants. Water Sci Technol 2010, 62:2970-2978.
120. Sahar E., Ernst M., Godehardt M., Hein A., Herr J., Melin T., et al. Comparison of two treatments for the removal of selected organic micropollutants and bulk organic matter: conventional activated sludge followed by ultrafiltration versus membrane bioreactor. Water Sci Technol 2011, 63:733-740.
121. Salgot M., Huertas E., Weber S., Dott W., Hollender J. Wastewater reuse and risk: definition of key objectives. Desalination 2006, 187:29-40.
122. Sanderson H., Johnson D.J., Wilson C.J., Brain R.A., Solomon K.R. Probabilistic hazard assessment of environmentally occurring pharmaceuticals toxicity to fish, daphnids and algae by ECOSAR screening. Toxicol Lett 2003, 144:83-395.
123. Santos J.L., Aparicio I., Alonso E. Occurrence and risk assessment of pharmaceutically active compounds in wastewater treatment plants. A case study: Seville city (Spain). Environ Int 2007, 33:596-601.
124. Santos J.L., Aparicio I., Callejon M., Alonso E. Occurrence of pharmaceutically active compounds during 1-year period in wastewater from four wastewater treatment plants in Seville (Spain). J Hazard Mater 2009, 164:1509-1516.
125. Schröder HFr Mass spectrometric monitoring of the degradation and elimination efficiency for hardly eliminable and hardly biodegradable polar compounds by membrane bioreactors. Water Sci Technol 2002, 46:57-64.
126. Sipma J., Osuna B., Collado N., Monclus H., Ferrero G., Comas J., et al. Comparison of removal of pharmaceuticals in MBR and activated sludge systems. Desalination 2010, 250:653-659.
127. Snyder S.A., Adham S., Redding A.M., Cannon F.S., DeCarolis J., Oppenheimer J., et al. Role of membranes and activated carbon in the removal of endocrine disruptors and pharmaceuticals. Desalination 2006, 202:156-181.
128. Strenn B., Clara M., Gans O., Kreuzinger N. Carbamazepine, diclofenac, ibuprofen and bezafibrate-investigations on the behaviour of selected pharmaceuticals during wastewater treatment. Water Sci Technol 2004, 50:269-276.
129. Stuer-Lauridsen F., Birkved M., Hansen L.P., Holten Luutzhù;ft H.C., Halling-Sørensen B., Halling-Sørensen B. Environmental risk assessment of human pharmaceuticals in Denmark after normal therapeutic use. Chemosphere 2000, 40:783-793.
130. Stumpf M., Ternes T.A., Wilken R.D., Rodrigues S.V., Baumann W. Polar drugs residues in sewage and natural waters in the state of Rio De Janeiro, Brazil. Sci Total Environ 1999, 225:135-141.
131. Suárez S., Ramil M., Omil F., Lema J.M. Removal of pharmaceutically active compounds in nitrifying-denitrifying plants. Water Sci Technol 2005, 52:9-14.
132. Suárez S., Carballa M., Omil F., Lema J.M. How are pharmaceutical and personal care products (PPCPs) removed from urban wastewaters?. Rev Environ Sci Biotechnol 2008, 7:125-138.
133. Suárez S., Lema J.M., Omil F. Removal of Pharmaceutical and Personal Care products(PPCPs) under nitrifying and denitrifying conditions. Water Res 2010, 44:3214-3224.
134. Tadkaew N., Sivakumar M., Khan S.J., McDonald J.A., Nghiem L.D. Effect of mixed liquor pH on the removal of trace organic contaminants in a membrane bioreactor. Bioresource Technol 2010, 101:1494-1500.
135. Tadkaew N., Hai F.I., McDonald J.A., Khan S.J., Nghiem L.D. Removal of trace organics by MBR treatment: the role of molecular properties. Water Res 2011, 45:2439-2451.
136. Tauxe-Wuersch A., De Alencastro L.F., Grandjean D., Tarradellas J. Occurrence of several acidic drugs in sewage treatment plants in Switzerland and risk assessment. Water Res 2005, 39:1761-1772.
137. Ternes T.A., Bonerz M., Herrmann N., Teiser B., Andersen H.R. Irrigation of treated wastewater in Braunschweig, Germany: an option to remove pharmaceuticals and musk fragrances. Chemosphere 2007, 66:894-904.
138. d) for pharmaceuticals and musk fragrances in sewage sludge. Wat Res 2004, 38:4075-4084.
139. Ternes T.A., Joss A. Human pharmaceuticals, hormones and fragrances. The challenge of micropollutants in urban water management 2006, IWA Publishing, London, p. 243-277, 406-439.
140. Ternes T.A., Stüber J., Herrmann N., McDowell D., Ried A., Kampmann M., et al. Ozonation: a tool for removal of pharmaceuticals, contrast media and musk fragrances from wastewaters?. Water Res 2003, 37:1976-1982.
141. Ternes T.A., Stumpf M., Mueller J., Heberer K., Wilken R.D., Servos M. Behaviour and occurrence of estrogens in municipal sewage treatment plants-I. Investigations in Germany, Canada and Brazil. Sci Total Environ 1999, 225:81-90.
142. Ternes T.A. Occurrence of drugs in German sewage treatment plants and rivers. Water Res 1998, 32:3245-3260.
143. Thomas P.M., Foster G.D. Tracking acidic pharmaceutical, caffeine, and triclosan through the wastewater treatment process. Environ Technol Chem 2005, 24:25-30.
144. Van der Aa N.G.F.M., Kommer G.J., Van Montfoort J.E., Versteegh J.F.M. Demographic projections of future pharmaceutical consumption in the Netherlands. Water Sci Technol 2011, 63:825-831.
145. Tunkel J., Howard P.H., Boethling R.S., Stiteler W., Loonen H. Predicting ready biodegradability in the Japanese ministry of international trade and industry test. Environ Toxicol Chem 2000, 19:2478-2485.
146. Urase T., Kagawa C., Kikuta T. Factors affecting removal of pharmaceutical substances and estrogens in membrane separation bioreactors. Desalination 2005, 178:107-113.
147. US EPA, 1999. Search in Ecotoxicology Database System (U.S. EPA MED-Duluth) Available from: http://www.epa.gov/medecotx/ecotoxhome.htm.
148. US EPA, 2009. Nutrient Control Design Manual State of technology Review Report EPA/600/R-09/012 January 2009 Available from: (last access March 27th 2012). http://www.epa.gov/nrmrl.
149. Vieno N.M., Tuhkanen T., Kronberg L. Seasonal variation in the occurrence of pharmaceuticals in effluents from a sewage treatment plant and in the recipient water. Environ Sci Technol 2005, 39:8220-8226.
150. Vieno N., Tuhkanen T., Kronberg L. Elimination of pharmaceuticals in sewage treatment plants in Finland. Water Res 2007, 41:1001-1012.
151. Watkinson A.J., Murby E.J., Costanzo S.D. Removal of antibiotics in conventional and advanced wastewater treatment: implications for environmental discharge and wastewater recycling. Water Res 2007, 41:4164-4176.
152. Weigel S., Berger U., Jensen E., Kallenborn R., Thoresen H., Hühnerfuss H. Determination of selected pharmaceuticals and caffeine in sewage and seawater from Tromsø/Norway with emphasis on ibuprofen and its metabolites. Chemosphere 2004, 56:583-592.
153. Weiss S., Reemtsma T. Membrane bioreactors for municipal wastewater treatment-a viable option to reduce the amount of polar pollutants discharged into surface waters?. Water Res 2008, 42:3837-3847.
154. Wick A., Fink G., Siegriest H., Ternes T.A. Fate of beta blockers and psycho-active drugs in conventional wastewater treatment. Water Res 2009, 43:1060-1074.
155. Xu W.H., Zhang G., Li X.D., Zou S.C., Li P., Hu Z.H., et al. Occurrence and elimination of antibiotics at four sewage treatment plants in the Pearl river delta (PRD), South China. Water Res 2007, 41:4526-4534.
156. Yasojima M., Nakada N., Komori K., Suzuki Y., Tanaka H. Occurrence of levofloxacin, clarithromycin and azithromycin in wastewater treatment plant in Japan. Water Sci Technol 2006, 53:227-233.
157. Yu J.T., Bouwer E.J., Coelhan M. Occurrence and biodegradability studies of selected pharmaceuticals and personal care products in sewage effluent. Agr Water Manage 2006, 86:72-80.
158. Ziylan A., Ince N.H. The occurrence and fate of anti-inflammatory and analgesic pharmaceuticals in sewage and fresh water: treatability by conventional and non conventional processes. J Hazard Mater 2011, 187:24-37.
159. Zorita S., Martensson L., Mathiasson L. Occurrence and removal of pharmaceuticals in municipal sewage treatment system in the south of Sweden. Sci Total Environ 2009, 407:2760-2770.
160. Zwiener C., Frimmel F.H. Short term tests with a pilot sewage plant and biofilm reactors for the biological degradation of the pharmaceutical compounds clofibric acid, ibuprofen, and diclofenac. Sci Total Environ 2003, 309:201-211.